Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma.
Saved in:
| Title: | Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. |
|---|---|
| Authors: | Safari M; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Scotto L; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA., Basseville A; Omics Data Science Unit, Institut de Cancérologie de l'Ouest; F-, Angers 49055, France., Litman T; University of Copenhagen, Copenhagen, Denmark., Xue H; Department of Chemistry and Biochemistry & The Baylor Synthesis and Drug-Lead Discovery Lab, Baylor University, Waco, TX, USA., Petrukhin L; James J Peters VA Medical Center; New York, NY, USA., Zhou P; James J Peters VA Medical Center; New York, NY, USA., Remotti HE; Department of Pathology, Columbia University Irving Medical Center, New York, NY, USA., Ku A; Department of Pathology, Columbia University Irving Medical Center, New York, NY, USA., Morales DV; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Damoci C; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Zhu M; Department of Chemistry and Biochemistry & The Baylor Synthesis and Drug-Lead Discovery Lab, Baylor University, Waco, TX, USA., Maddipati R; Department of Internal Medicine and Children's Research Institute, UT Southwestern Medical Center, Dallas, TX, USA., Hull KG; Department of Chemistry and Biochemistry & The Baylor Synthesis and Drug-Lead Discovery Lab, Baylor University, Waco, TX, USA., Robey RW; Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Olive KP; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Fojo T; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA; James J Peters VA Medical Center; New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Romo D; Department of Chemistry and Biochemistry & The Baylor Synthesis and Drug-Lead Discovery Lab, Baylor University, Waco, TX, USA., Bates SE; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA; James J Peters VA Medical Center; New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA. Electronic address: seb2227@cumc.columbia.edu. |
| Source: | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy [Drug Resist Updat] 2026 Jan; Vol. 84, pp. 101312. Date of Electronic Publication: 2025 Oct 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Churchill Livingstone Country of Publication: Scotland NLM ID: 9815369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2084 (Electronic) Linking ISSN: 13687646 NLM ISO Abbreviation: Drug Resist Updat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
